Showing 2441-2450 of 3039 results for "".
- Nanodropper Launches 2022 Give the Gift of Vision Campaign to Support Global Access to Eye Carehttps://modernod.com/news/nanodropper-launches-2022-give-the-gift-of-vision-campaign-to-support-global-access-to-eye-care-1/2481275/Nanodropper has launched its 2022 Give the Gift of Vision program, an effort to donate 1,000 Nanodropper Adaptors to at-need patients in the United States and its global nonprofit partners, aiming to deliver better access to vision-saving care in low resource settings in Africa, Haiti, and e
- Re-Vana Therapeutics Raises $11.9 Million to Advance Drug Delivery Productshttps://modernod.com/news/re-vana-therapeutics-raises-119-million-to-advance-drug-delivery-products/2481266/Re-Vana Therapeutics announced the closure of its Series A round with $11.9 million in funding, an oversubscription of $4 million. The proceeds will advance the development of Re-Vana's novel and proprietary photo-crosslinked EyeLief, EyeLief-SD, and OcuLief 
- New UCI-Led Study Shows Repeated Stress Accelerates Aging of the Eyehttps://modernod.com/news/new-uci-led-study-shows-repeated-stress-accelerates-aging-of-the-eye/2481260/New research from the University of California, Irvine, suggests aging is an important component of retinal ganglion cell death in glaucoma, and that novel pathways can be targeted when designing new treatments for glaucoma patients. The study, titled, “
- FDA Grants Breakthrough Therapy Designation for Iveric Bio's Avacincaptad Pegol for Geographic Atrophyhttps://modernod.com/news/fda-grants-breakthrough-therapy-designation-for-iveric-bios-avacincaptad-pegol-for-geographic-atrophy/2481251/Iveric bio announced that the FDA has granted Breakthrough Therapy designation for avacincaptad pegol (ACP, also known as Zimura), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). To date, A
- GenSight Biologics Announces Publication of Results of Lumevoq REFLECT Pivotal Clinical Trialhttps://modernod.com/news/gensight-biologics-announces-publication-of-results-of-lumevoq-reflect-pivotal-clinical-trial/2481250/GenSight Biologics announced that the neurology journal BRAIN has published efficacy and safety findings at 1.5-year post-treatment in ND4-LHON patients treated with lenadogene nolparvovec (Lumevoq) from the REFLECT pivotal clinical trial. The REF
- EssilorLuxottica Supports New WSPOS Independent Medical Education Program on Myopia Managementhttps://modernod.com/news/essilorluxottica-supports-new-wspos-independent-medical-education-program-on-myopia-management/2481243/EssilorLuxottica announced it is supporting the World Society of Paediatric Ophthalmology and Strabismus (WSPOS) independent medical education program on myopia management, as a gold level supporter, which will be launched on November 19 and 20, at 2-4pm GMT. The key goals of this progr
- Harrow Launches Atropine.comhttps://modernod.com/news/harrow-launches-atropinecom/2481236/Harrow announced the launch of atropine.com, an ordering and marketing portal designed specifically for prescribers interested in compounded atropine formulations. All atropine.com, prescriptions will be dispensed through Harrow’s wholly owned
- Nicox Outlines Future Development and Partnering Plans for NCX 470https://modernod.com/news/nicox-outlines-future-development-and-partnering-plans-for-ncx-470-in-glaucoma/2481228/Nicox SA announced future development and partnering plans for NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, currently in phase 3 development for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. “Our market research&nbs
- Iveric Bio Submits First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophyhttps://modernod.com/news/iveric-bio-submits-first-part-of-nda-for-rolling-review-of-avacincaptad-pegol-for-the-treatment-of-geographic-atrophy/2481227/Iveric bio announced that it has submitted to the FDA the first part of its new drug application (NDA) for rolling review of avacincaptad pegol (ACP, also known as Zimura) a novel investigational complement C5 inhibitor, for the treatment of geographic atrophy (GA) secondary to age-related m
- Verana Health to Present Findings of Studies Using AAO IRIS Registry Data to Advance Insights into Real World Outcomes in Treating AMDhttps://modernod.com/news/verana-health-to-present-findings-of-studies-using-aao-iris-registry-data-to-advance-insights-into-real-world-outcomes-in-treating-amd/2481222/During The Retina Society’s 55th Annual Scientific Meeting Nov. 2-5, Verana Health will present findings on two studies that utilize curated real-world data (RWD) from the American Academy of Ophthalmology (Academy)